Depth is not a dose

Sedation depth is a state the patient is in, defined in the multisociety guidelines by how the patient responds and whether airway, breathing and circulation are maintained, not a property of the amount given, and patients move along that continuum in both directions during a case. The same amount produces different depths because clearance varies between people and with interacting drugs (a week of erythromycin increased oral midazolam exposure more than four-fold in volunteers), because older patients respond more at the same concentration, and because effect lags behind administration: in an EEG study midazolam's blood–brain equilibration half-time was about five minutes, so a second increment given on the strength of an unfinished first one lands on a still-rising effect, and in healthy volunteers repeated sublingual triazolam kept deepening sedation for hours, reaching deep levels in eight of ten subjects in one study. The gap between intended and achieved depth is real but mostly measured outside dentistry: in one endoscopy study of an opioid–benzodiazepine regimen intended for moderate sedation, 68% of patients reached deep sedation at least once, and a PubMed search in November 2026 located no equivalent measurement in benzodiazepine-only dental sedation. The response described here is to give very little at a time, stop and let the drug's offset bring the patient back if they go deeper than intended, avoid agents whose half-lives or metabolites accumulate, and avoid pairing a benzodiazepine with an opioid, whose separate effects on breathing drive and airway tone become hard to tell apart when the airway starts to fail. Rescue from a deeper level depends first on recognising that the patient has reached it, and even the reliability of the offset depends on the patient: in a small intensive-care series, midazolam's conjugated metabolite accumulated in severe renal failure and prolonged sedation.